XML 48 R31.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | 60 Months Ended | 114 Months Ended
--- | --- | --- | --- | --- | ---
Jan. 31, 2019 | Feb. 28, 2017 | Mar. 31, 2015 | Jun. 30, 2010 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2019 | Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 244,010,000 | $ 222,094,000 | $ 183,580,000 | $ 138,403,000 | $ 131,492,000 | $ 151,757,000 | $ 96,905,000 | $ 71,086,000 | $ 788,087,000 | $ 451,240,000 | $ 161,626,000 |  |
Acquired in-process research and development |  |  |  |  |  |  |  |  |  |  |  |  | 154,272,000 | 4,750,000 | 30,000,000 |  |
Restricted investment in equity securities fair value amount |  |  |  |  | 55,868,000 |  |  |  |  |  |  |  | 55,868,000 |  |  | $ 55,868,000 | $ 55,868,000
Development and Regulatory Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  | 4,900,000,000 |  |  |  |  |  |  |  | 4,900,000,000 |  |  | 4,900,000,000 | 4,900,000,000
AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments received |  |  |  | $ 75,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  | 40,000,000.0 | 30,000,000.0 |  |
Patent rights period |  |  |  | ten years or the life of the related patent rights. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement right description |  |  |  | We will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration termination notice period |  |  |  | 180 days |  |  |  |  |  |  |  |  |  |  |  |  |
AbbVie | Royalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  | 14,300,000 | 1,600,000 |  |  |
AbbVie | Regulatory and Clinical Results and FDA Acceptance Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000.0 |  |  |  |
AbbVie | Topic 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments received |  |  |  | $ 75,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
AbbVie | Development and Regulatory Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and regulatory milestone payment receipts |  |  |  | 480,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 135,000,000.0
AbbVie | Commercial Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential commercial milestone payment receipts |  |  |  | $ 50,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
B I A L |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development |  | $ 30,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
B I A L | Parkinson's Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential payments for regulatory milestones |  |  |  |  | 20,000,000.0 |  |  |  |  |  |  |  | 20,000,000.0 |  |  | 20,000,000.0 | 20,000,000.0
B I A L | Event Based Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments made for regulatory milestones |  |  |  |  | 10,000,000.0 |  |  |  |  |  |  |  | 10,000,000.0 |  |  | 10,000,000.0 | 10,000,000.0
B I A L | R&D Expense and FDA Acceptance Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments made for regulatory milestones |  |  |  |  |  |  | 10,000,000.0 |  |  |  |  |  |  |  |  |  |
B I A L | Regulatory Approval and Net Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  | $ 95,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voyager Therapeutics | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration termination notice period | 180 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments made | $ 115,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted investment in equity securities cost | $ 50,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price | $ 11.9625 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted investment in equity securities fair value amount | $ 54,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voyager Therapeutics | Collaboration and License Agreement | IPR&D |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development |  |  |  |  |  |  | $ 5,000,000.0 | $ 113,100,000 |  |  |  |  |  |  |  |  |
Voyager Therapeutics | Collaboration and License Agreement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted investment in equity securities number of shares | 4.2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voyager Therapeutics | Collaboration and License Agreement | Development, Regulatory and Commercial Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments | $ 1,700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Xenon | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments made |  |  |  |  | 30,000,000.0 |  |  |  |  |  |  |  | 30,000,000.0 |  |  | 30,000,000.0 | 30,000,000.0
Restricted investment in equity securities cost |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  | $ 20,000,000.0 | $ 20,000,000.0
Share price |  |  |  |  | $ 14.196 |  |  |  |  |  |  |  | $ 14.196 |  |  | $ 14.196 | $ 14.196
Restricted investment in equity securities fair value amount |  |  |  |  | $ 14,100,000 |  |  |  |  |  |  |  | $ 14,100,000 |  |  | $ 14,100,000 | $ 14,100,000
Xenon | Collaboration and License Agreement | IPR&D |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development |  |  |  |  | $ 36,200,000 |  |  |  |  |  |  |  |  |  |  |  |
Xenon | Collaboration and License Agreement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted investment in equity securities number of shares |  |  |  |  | 1.4 |  |  |  |  |  |  |  | 1.4 |  |  | 1.4 | 1.4
Xenon | Collaboration and License Agreement | Development, Regulatory and Commercial Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  | $ 1,700,000,000 |  |  |  |  |  |  |  | $ 1,700,000,000 |  |  | $ 1,700,000,000 | $ 1,700,000,000
Mitsubishi Tanabe |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments received |  |  | $ 30,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000.0 |  |
Patent rights period |  |  | the longer of ten years or the life of the related patent rights. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement right description |  |  | Under the terms of the agreement, MTPC is responsible for all third-party development, marketing and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to us. We do not directly control when event-based payments will be achieved or when royalty payments will begin. MTPC may terminate the agreement at its discretion upon 180 days’ written notice to us. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to us. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration termination notice period |  |  | 180 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment receipts |  |  | $ 85,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues recognized under collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  | 20,600,000 |
Deferred revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  | 900,000 |  |  |  |
Up-front license fees |  |  | $ 30,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenues |  |  |  |  | $ 9,400,000 |  |  |  |  |  |  |  | $ 9,400,000 |  |  | $ 9,400,000 | $ 9,400,000

X
- Definition Milestone revenue, sponsored research and development, and amortization of up front licensing fees recognized during the period under a collaborative agreement with a third-party. + References No definition available. + Details
Name: | nbix_CollaborationRevenue
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Up front payments received (paid) under collaborative agreements for sponsored research and development, and licensing fees + References No definition available. + Details
Name: | nbix_CollaborativeArrangementUpfrontPaymentReceivedPaid
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period of time the company is entitled to a percentage of worldwide sales under the collaboration agreement. + References No definition available. + Details
Name: | nbix_ContractTerminationProvisionTerm
Namespace Prefix: | nbix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments made for regulatory milestones under a collaboration agreement + References No definition available. + Details
Name: | nbix_PaymentsMadeForRegulatoryMilestones
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential commercial milestone payment receipts under a collaboration agreement. + References No definition available. + Details
Name: | nbix_PotentialCommercialMilestonePaymentReceipts
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development and regulatory milestone payment receipts under a collaboration agreement. + References No definition available. + Details
Name: | nbix_PotentialDevelopmentAndRegulatoryMilestonePaymentReceipts
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential later stage milestone payments and royalties. + References No definition available. + Details
Name: | nbix_PotentialMilestonePaymentReceipts
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of potential milestone payments to be paid under a license agreement. + References No definition available. + Details
Name: | nbix_PotentialMilestonePayments
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential payments for regulatory milestones under a collaboration agreement. + References No definition available. + Details
Name: | nbix_PotentialPaymentsForRegulatoryMilestones
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of time required for third party collaborator to give written notice prior to terminating the collaborative agreement. + References No definition available. + Details
Name: | nbix_TerminationNoticePeriod
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payments made under a collaboration agreement. + References No definition available. + Details
Name: | nbix_UpfrontPaymentsMade
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payments received under a collaboration agreement. + References No definition available. + Details
Name: | nbix_UpfrontPaymentsReceived
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of rights and obligations under the collaborative arrangements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_CollaborativeArrangementRightsAndObligations
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 30 -Section 50 -Paragraph 1A -Subparagraph (b)(1)(i) -URI http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729 + Details
Name: | us-gaap_EquitySecuritiesFvNiRestricted
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-12C.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_ClinicalDevelopmentAndRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RestatementAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_RegulatoryApprovalClinicalResultsAndFdaAcceptanceMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_CommercializationEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nbix_ParkinsonDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_EventBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_ResearchAndDevelopmentExpenseAndFDAAcceptanceMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_RegulatoryApprovalAndNetSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_ClinicalDevelopmentRegulatoryAndCommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |